AC220

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Leukemia, Myeloid, Acute

Conditions

Leukemia, Myeloid, Acute

Trial Timeline

Apr 1, 2012 → Mar 1, 2015

NCT ID

NCT01565668

About AC220

AC220 is a phase 2 stage product being developed by Daiichi Sankyo for Leukemia, Myeloid, Acute. The current trial status is completed. This product is registered under clinical trial identifier NCT01565668. Target conditions include Leukemia, Myeloid, Acute.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02675478	Phase 1	Completed	Feb 1, 2016	Nov 13, 2018	Relapsed AML
NCT01565668	Phase 2	Completed	Apr 1, 2012	Mar 1, 2015	Leukemia, Myeloid, Acute
NCT01468467	Phase 1	Completed	Apr 1, 2012	Mar 1, 2015	Leukemia, Myeloid, Acute
NCT00462761	Phase 1	Completed	Jan 1, 2007	Dec 1, 2009	Acute Myeloid Leukemia

Competing Products

20 competing products in Leukemia, Myeloid, Acute

See all competitors

Product	Company	Stage	Hype Score
AFM28	Affimed	Phase 1	25
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimen	CSPC Pharmaceutical Group Limited	Phase 2	51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells	CSPC Pharmaceutical Group Limited	Phase 2	51
TERN-701	Terns Pharmaceuticals	Phase 1/2	38
Fludarabine + Cyclophosphamide + PRGN-3007	Precigen	Phase 1	28
PRGN-3006 T Cells	Precigen	Phase 1	28
Bisantrene	Race Oncology	Phase 2	44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridine	Race Oncology	Phase 1	25
Bisantrene + Fludarabine + Clofarabine	Race Oncology	Phase 2	44
ZN-d5 ZN-c3 + ZN-c3	Zentalis Pharmaceuticals	Phase 1/2	33
ZN-d5	Zentalis Pharmaceuticals	Phase 1	25
Pirtobrutinib + Venetoclax + Rituximab	Eli Lilly	Phase 3	77
Pirtobrutinib	Eli Lilly	Phase 2	52
Ibrutinib + LY3214996	Eli Lilly	Phase 1	33
Pirtobrutinib + Acalabrutinib	Eli Lilly	Phase 2	52
VIP943 (QW) + VIP943 (BIW)	Vincerx Pharma	Phase 1	25
Pirtobrutinib + Ibrutinib	Eli Lilly	Phase 3	77
LY2523355	Eli Lilly	Phase 1	33
Tomivosertib	eFFECTOR Therapeutics	Phase 1	25
gemtuzumab ozogamycin	Chugai Pharmaceutical	Phase 3	77

Other Products from Daiichi Sankyo

Olmesartan medoxomil + Olmesartan medoxomil/hydrochlorothiazide + HydrochlorothiazideApproved

OAC aloneApproved

olmesartan medoxomil + Placebo + losartan potassiumApproved

Prasugrel + ClopidogrelApproved

Diet+pravastatinApproved